Evidence map›Paper›PMID 27899815›Full record

ReviewNature reviews. Gastroenterology & hepatology2017

Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.

Siddharth Singh, Parambir S Dulai, Amir Zarrinpar, Sonia Ramamoorthy, William J Sandborn

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05196958 (Interest of GLP1 Analogues), which is not on this map. Cited by 234 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 13 pooled it
17.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05196958 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)

TypeinterventionalSponsorFondation Hôpital Saint-JosephRan2022 to 2024Enrolled20ConditionsInflammatory Bowel Diseases, Diabetes Mellitus, Type 2ArmsGLP1 analogues
3 · Its place in the literature

Who cites it

234 citing papers in PubMed, 13 syntheses or guidelines pooled it, 432 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

174 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Siddharth SinghDivision of Gastroenterology, Department of Medicine, University of California San Diego, USA.
Parambir S DulaiDivision of Gastroenterology, Department of Medicine, University of California San Diego, USA.
Amir ZarrinparDivision of Gastroenterology, Department of Medicine, University of California San Diego, USA.
Sonia RamamoorthyDivision of Colon and Rectal Surgery, Department of Surgery, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92193, USA.
William J SandbornDivision of Gastroenterology, Department of Medicine, University of California San Diego, USA.
University of California, San Diego · US

Funding

San Diego Biomedical Informatics Education & Research (SABER)T15LM011271 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAMIM NEMATI · 2012 to 2026
$9.7M
Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
San Diego Clinical and Translational Research InstituteKL2TR000099 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2014
$1.1M
The Relationship of Gut Microbiome and Time Restricted Feeding in MetabolismK08DK102902 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZARRINPAR, AMIR · 2015 to 2019
$789k
NCATS NIH HHS KL2 TR000099NIDDK NIH HHS K08 DK102902NIDDK NIH HHS T32 DK007202NLM NIH HHS T15 LM011271
6 · The paper itself

Abstract

Incidence of IBD is rising in parallel with overweight and obesity. Contrary to conventional belief, about 15-40% of patients with IBD are obese, which might contribute to the development of IBD. Findings from cross-sectional and retrospective cohort studies are conflicting on the effect of obesity on natural history and course of IBD. Most studies are limited by small sample size, low event rates, non-validated assessment of disease activity and lack robust longitudinal follow-up and have incomplete adjustment for confounding factors. The effect of obesity on the efficacy of IBD-related therapy remains to be studied, though data from other autoimmune diseases suggests that obesity results in suboptimal response to therapy, potentially by promoting rapid clearance of biologic agents leading to low trough concentrations. These data provide a rationale for using weight loss interventions as adjunctive therapy in patients with IBD who are obese. Obesity also makes colorectal surgery technically challenging and might increase the risk of perioperative complications. In this Review, we highlight the existing literature on the epidemiology of obesity in IBD, discuss its plausible role in disease pathogenesis and effect on disease course and treatment response, and identify high-priority areas of future research.

Indexed as

Combined Modality TherapyDisease ProgressionEuropeHumansInflammatory Bowel DiseasesNorth AmericaObesityPrevalenceRisk FactorsTreatment Outcome

Identifiers

PMID27899815
PMCPMC5550405
OpenAlexW2559678284

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.